News

Under the agreement, Abbott will offer its HIV viral load tests – which monitor the amount of HIV in a person’s blood – at reduced prices to help

The deal, facilitated by J&J Innovation, will see the two firms jointly develop and commercialize RNA-based drug products to treat specified diseases using Arcturus’ UNA Oligomer chemistry and

PADAC has recommended the drug through a unanimous voting of 14 to zero, supporting the biologics licence application (BLA) for mepolizumab as an add-on maintenance treatment for severe

Around 60 individuals will be included in this multi-center, randomized, double-blind, placebo-controlled, two arm, parallel group Phase II trial of ADS-5102. During the trial, all patients will be

The trial did not meet its primary objective to show superior efficacy of desvenlafaxine succinate sustained-release formulation compared to placebo. The company said that this is the first

BIND is a clinical-stage nanomedicine company that develops targeted and programmable therapeutics called Accurins. Following achievement of proof-of-concept, both the firms intend to expand the collaboration to develop

Last year, the company secured orphan drug designation from the US Food and Drug Administration (FDA) for Epidiolex to treat LGS. The company intends to report top-line data

The drug is approved for these children who have had an insufficient response to corticosteroids, immunoglobulins or splenectomy. Earlier in 2008, the FDA approved Promacta for use in

The patent covers the use of this therapeutic for treating dyskinesia associated with L-DOPA therapy in Parkinson’s disease. "This recent patent award will provide robust protection for MLR-1019